JPMorgan Chase & Co. Has $411,000 Stake in Heron Therapeutics, Inc. (NASDAQ:HRTX)

JPMorgan Chase & Co. boosted its position in Heron Therapeutics, Inc. (NASDAQ:HRTX) by 295.8% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 206,711 shares of the biotechnology company’s stock after purchasing an additional 154,487 shares during the quarter. JPMorgan Chase & Co. owned about 0.14% of Heron Therapeutics worth $411,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. B. Riley Wealth Advisors Inc. acquired a new position in Heron Therapeutics during the second quarter worth about $41,000. Sei Investments Co. acquired a new position in shares of Heron Therapeutics during the second quarter worth $44,000. Cutter & CO Brokerage Inc. bought a new stake in shares of Heron Therapeutics in the third quarter worth $39,000. Y Intercept Hong Kong Ltd acquired a new stake in Heron Therapeutics in the third quarter valued at $39,000. Finally, Capstone Investment Advisors LLC bought a new stake in shares of Heron Therapeutics in the 3rd quarter valued at about $45,000. 80.01% of the stock is currently owned by institutional investors and hedge funds.

Heron Therapeutics Stock Performance

Heron Therapeutics stock opened at $1.67 on Thursday. The stock has a market capitalization of $254.01 million, a price-to-earnings ratio of -9.28 and a beta of 1.60. Heron Therapeutics, Inc. has a 52-week low of $1.04 and a 52-week high of $3.93. The stock’s 50 day moving average price is $1.54 and its two-hundred day moving average price is $1.88.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($0.03) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.03). The firm had revenue of $32.81 million for the quarter, compared to analyst estimates of $36.40 million. During the same period last year, the company posted ($0.17) earnings per share. On average, equities research analysts forecast that Heron Therapeutics, Inc. will post -0.13 EPS for the current year.

Wall Street Analyst Weigh In

HRTX has been the subject of a number of analyst reports. Needham & Company LLC restated a “buy” rating and set a $4.00 price objective on shares of Heron Therapeutics in a research report on Wednesday, December 4th. StockNews.com downgraded shares of Heron Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.